<div id="readability-page-1"><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has shared an announcement. Shanghai Junshi Biosciences announced that shareholder Shanghai Tanying Investment Partnership (LP), a private equity fund and pre-IPO investor, currently holds 59,459,326 A shares, representing 5.7914% of the company’s total share capital, with these shares freely tradable since July 2021. Owing to fund maturity and liquidity needs, Shanghai Tanying plans to trim its stake by up to 20,533,797 shares, or no more than 2% of the company’s total share capital, via block trades, signaling a portfolio adjustment rather than a shift in its stated long-term positive view of Junshi’s prospects and providing the market with clarity on potential share overhang. The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page. More about Shanghai Junshi Biosciences Co., Ltd. Class H Shanghai Junshi Biosciences Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong and on Shanghai’s STAR Market. The company focuses on innovative drug R&amp;D and commercialization, serving China’s healthcare market and international investors through dual listings in major capital markets. Average Trading Volume: 4,201,539 Technical Sentiment Signal: Strong Buy Current Market Cap: HK$44.49B For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.</div>

688180

01877

159837

Shanghai Junshi Biosciences Co., Ltd. announced that shareholder Shanghai Tanying Investment Partnership plans to reduce its stake by up to 2%, or 20,533,797 shares, due to fund maturity and liquidity needs. This adjustment reflects a portfolio change rather than a negative outlook on Junshi's prospects. The company, listed in Hong Kong and Shanghai, focuses on innovative drug R&D. The latest analyst rating for Junshi's stock is a Hold with a price target of HK$34.70.

Tip Ranks

Junshi Biosciences

JUNSHI BIO

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

Junshi Biosciences Shareholder Plans Up to 2% Stake Reduction